ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Azacitidine

Also written as “azacitidine”, “Azacitidine (AZA)” and “Eganelisib in combination with azacitidine”.

Its studies are mostly in Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Hematologic Neoplasms · Lymphoma, T-Cell, led by 9 companies.

Drug pageAzacitidine: every studyMany companies study it; this page follows only the 27 they lead. All 441 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 201027 company-led studies, 3 open or runningNext primary completion: Jul 13, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only161 open or runningphase 4since Sep 13, 2010Oct 31, 2003none ahead
Takedaits history only30 open or runningphase 3since Aug 30, 2017May 28, 2009none ahead
Hikma Pharmaceuticalsits history only21 open or runningphase 1since Mar 11, 2024Mar 11, 2024none ahead
Bioniche Pharma USAits history only10 open or runningphase 1since Jun 25, 2010Jun 25, 2010none ahead
Johnson & Johnsonits history only10 open or runningphase 2since Feb 7, 2020Feb 7, 2020none ahead
Merckits history only10 open or runningphase 2since Nov 24, 2014Nov 24, 2014none ahead
Nanexa ABits history only10 open or runningphase 1since May 11, 2021May 11, 2021none ahead
Nob Hill Therapeuticsits history only11 open or runningphase 2since Sep 10, 2026Sep 10, 2026Jul 13, 2029phase 2 · NCT07864584
Sarah Cannon Research Institute10 open or runningphase 2since Oct 4, 2006Oct 4, 2006none ahead

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical, Hoffmann-La Roche, Roche-Genentech, Takeda Development Center Americas and argenx.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sarah Cannon Research Institute only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 4, 2006First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT00384839 · 36 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Sarah Cannon Research Institute leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00384839Prostatic Neoplasms · United States2CompletedNov 200936

How it is read

Names in the registry

  • “Azacitidine”, 36 entries
  • “azacitidine”, 8 entries
  • “Azacitidine (AZA)”, 2 entries
  • “Eganelisib in combination with azacitidine”, 1 entry
  • “NHT102”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.